Increased cerebral cannabinoid-1 receptor availability is a stable feature of functional dyspepsia: A [18 F]MK-9470 PET study

Psychotherapy and Psychosomatics

Volumn 84, Issue 3, 2015, Pages 149-158

  Ly, Huynh Giao ^a   Ceccarini, Jenny ^c   Weltens, Nathalie ^a   Bormans, Guy ^b   Van Laere, Koen ^c   Tack, Jan ^a   Van Oudenhove, Lukas ^a,c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Department of Pharmaceutical and Pharmacological Sciences   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cannabinoid 1 receptor; Endocannabinoids; Functional dyspepsia; Positron emission tomography; Somatic symptom disorders

Indexed keywords

CANNABINOID 1 RECEPTOR; FLUORINE 18 MK 9470; RADIOISOTOPE; UNCLASSIFIED DRUG; CNR1 PROTEIN, HUMAN; MK-9470; PYRIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; ANTERIOR CINGULATE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPEPSIA; FEMALE; FOLLOW UP; FOOD INTAKE; HUMAN; HYPOTHALAMUS; IN VIVO STUDY; INSULA; MALE; NOCICEPTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; VENTRAL STRIATUM; ANXIETY DISORDER; BODY MASS; BRAIN; COMORBIDITY; DIAGNOSTIC USE; METABOLISM; MIDDLE AGED; MOOD DISORDER; SCINTISCANNING;

ADULT; ANXIETY DISORDERS; BODY MASS INDEX; BRAIN; COMORBIDITY; DYSPEPSIA; FEMALE; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIOPHARMACEUTICALS; RECEPTOR, CANNABINOID, CB1;

EID: 84926228838     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000375454     Document Type: Article

References (61)

1. Tack J, Talley NJ: Functional dyspepsia - symptoms, definitions and validity of the Rome III criteria. Nat Rev Gastroenterol Hepatol 2013; 10: 134-141.
2. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada J-R, Stanghellini V: Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466-1479.
3. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J: Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115: 1346-1352.
4. Tack J, Caenepeel P, Fischler B, Piessevaux H, Janssens J: Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001; 121: 526-535.
5. Tack J, Demedts I, Dehondt G, Caenepeel P, Fischler B, Zandecki M, Janssens J: Clinical and pathophysiological characteristics of acute-onset functional dyspepsia. Gastroenterology 2002; 122: 1738-1747.
6. Tack J, Jones MP, Karamanolis G, Coulie B, Dubois D: Symptom pattern and pathophysiological correlates of weight loss in tertiaryreferred functional dyspepsia. Neurogastroenterol Motil 2010; 22: 29-35, e4-5.
7. Piessevaux H, De Winter B, Louis E, Muls V, De Looze D, Pelckmans P, Deltenre M, Urbain D, Tack J: Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neurogastroenterol Motil 2009; 21: 378-388.
8. Jones MP, Talley NJ, Eslick GD, Dubois D, Tack J: Community subgroups in dyspepsia and their association with weight loss. Am J Gastroenterol 2008; 103: 2051-2060.
9. Lacy BE, Weiser KT, Kennedy AT, Crowell MD, Talley NJ: Functional dyspepsia: the economic impact to patients. Aliment Pharmacol Ther 2013; 38: 170-177.
10. Dimsdale JE, Creed F, Escobar J, Sharpe M, Wulsin L, Barsky A, Lee S, Irwin MR, Levenson J: Somatic symptom disorder: an important change in DSM. J Psychosom Res 2014; 75: 223-228.
11. Van Oudenhove L, Aziz Q: The role of psychosocial factors and psychiatric disorders in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013; 10: 158-167.
12. Kanaan RAA, Lepine JP, Wessely SC: The association or otherwise of the functional somatic syndromes. Psychosom Med 2007; 69: 855-859.
13. Kim SE, Chang L: Overlap between functional GI disorders and other functional syndromes: what are the underlying mechanisms? Neurogastroenterol Motil 2012; 24: 895-913.
14. Henningsen P, Zimmermann T, Sattel H: Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med 2003; 65: 528-533.
15. Van Oudenhove L, Aziz Q: Recent insights on central processing and psychological processes in functional gastrointestinal disorders. Dig Liver Dis 2009; 41: 781-787.
16. Vanheel H, Farré R: Changes in gastrointestinal tract function and structure in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013; 10: 142-149.
17. Elsenbruch S: Abdominal pain in irritable bowel syndrome: a review of putative psychological, neural and neuro-immune mechanisms. Brain Behav Immun 2011; 25: 386-394.
18. Kennedy PJ, Clarke G, Quigley EMM, Groeger JA, Dinan TG, Cryan JF: Gut memories: towards a cognitive neurobiology of irritable bowel syndrome. Neurosci Biobehav Rev 2012; 36: 310-340.
19. Mayer EA, Naliboff BD, Craig AD: Neuroimaging of the brain-gut axis: from basic understanding to treatment of functional GI disorders. Gastroenterology 2006; 131: 1925-1942.
20. Van Oudenhove L, Vandenberghe J, Dupont P, Geeraerts B, Vos R, Dirix S, Bormans G, Vanderghinste D, Van Laere K, Demyttenaere K, Fischler B, Tack J: Abnormal regional brain activity during rest and (anticipated) gastric distension in functional dyspepsia and the role of anxiety: a H(2)(15)O-PET study. Am J Gastroenterol 2010; 105: 913-924.
21. Zeng F, Qin W, Liang F, Liu J, Tang Y, Liu X, Yuan K, Yu S, Song W, Liu M, Lan L, Gao X, Liu Y, Tian J: Abnormal resting brain activity in patients with functional dyspepsia is related to symptom severity. Gastroenterology 2011; 141: 499-506.
22. Tillisch K, Mayer EA, Labus JS: Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology 2011; 140: 91-100.
23. Gracely R, Ambrose K: Neuroimaging of fibromyalgia. Best Pract Res Clin Rheumatol 2011; 25: 271-284.
24. Gündel H, Valet M, Sorg C, Huber D, Zimmer C, Sprenger T, Tölle TR: Altered cerebral response to noxious heat stimulation in patients with somatoform pain disorder. Pain 2008; 137: 413-421.
25. Valet M, Gundel H, Sprenger T, Sorg C, Muhlau M, Zimmer C, Henningsen P, Tolle TR: Patients with pain disorder show graymatter loss in pain-processing structures: a voxel-based morphometric study. Psychosom Med 2009; 71: 49-56.
26. Mayer EA, Bushnell MC: Functional pain disorders: time for a paradigm shift?; in Mayer EA, Bushnell MC (eds): Functional Pain Syndromes: Presentation and Pathophysiology. Seattle, IASP Press, 2009, pp 531-565.
27. Mayer EA, Tillisch K: The brain-gut axis in abdominal pain syndromes. Annu Rev Med 2011; 62: 381-396.
28. Farmer AD, Aziz Q: Visceral pain hypersensitivity in functional gastrointestinal disorders. Br Med Bull 2009; 91: 123-136.
29. Wilson RI, Nicoll RA: Endocannabinoid signaling in the brain. Science 2002; 296: 678-682.
30. Katona I, Freund TF: Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 2008; 14: 923-930.
31. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564.
32. Guindon J, Hohmann AG: The endocannabinoid system and pain. CNS Neurol Disord Drug Targets 2009; 8: 403-421.
33. Wilson-Poe AR, Morgan MM, Aicher SA, Hegarty DM: Distribution of CB 1 cannabinoid receptors and their relationship with mu-opioid receptors in the rat periaqueductal gray. Neuroscience 2012; 213: 191-200.
34. Di Marzo V, Ligresti A, Cristino L: The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation. Int J Obes 2009; 33(suppl 2):S18-S24.
35. Bermudez-Silva FJ, Cardinal P, Cota D: The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J Psychopharmacol 2012; 26: 114-124.
36. Gérard N, Pieters G, Goffin K, Bormans G, Van Laere K: Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa. Biol Psychiatry 2011; 70: 777-784.
37. Burns HD, Van Laere K, Sanabria-Bohórquez S, Hamill TG, Bormans G, Eng WS, Gibson R, Ryan C, Connolly B, Patel S, Krause S, Vanko A, Van Hecken A, Dupont P, De Lepeleire I, Rothenberg P, Stoch SA, Cote J, Hagmann WK, Jewell JP, Lin LS, Liu P, Goulet MT, Gottesdiener K, Wagner JA, de Hoon J, Mortelmans L, Fong TM, Hargreaves RJ: [18 F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci USA 2007; 104: 9800-9805.
38. Van Vliet IM, de Beurs E: The MINI-International Neuropsychiatric Interview. A brief structured diagnostic psychiatric interview for DSM-IV in ICD-10 psychiatric disorders (in Dutch). Tijdschr Psychiatr 2007; 49: 393-397.
39. Cuomo R, Sarnelli G, Grasso R, Bruzzese D, Pumpo R, Salomone M, Nicolai E, Tack J, Budillon G: Functional dyspepsia symptoms, gastric emptying and satiety provocative test: analysis of relationships. Scand J Gastroenterol 2001; 36: 1030-1036.
40. Kroenke K, Spitzer RL, Williams JBW: The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002; 64: 258-266.
41. Sirri L, Grandi S, Fava GA: The Illness Attitude Scales. A clinimetric index for assessing hypochondriacal fears and beliefs. Psychother Psychosom 2008; 77: 337-350.
42. de Gier M, Vlaeyen JWS, Van Breukelen G, Stomp SGM, ter Kuile M, Kole-Snijders AMJ, Spinhoven P: Pijn coping en cognitie lijst. Validering en normgegevens. Maastricht, Pijnkenniscentrum Maastricht, 2004.
43. Van Laere K, Goffin K, Casteels C, Dupont P, Mortelmans L, de Hoon J, Bormans G: Gender- dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [18 F]MK-9470 PET. Neuroimage 2008; 39: 1533-1541.
44. Sanabria-Bohórquez SM, Hamill TG, Goffin K, De Lepeleire I, Bormans G, Burns HD, Van Laere K: Kinetic analysis of the cannabinoid-1 receptor PET tracer [18 F]ML-9470 in human brain. Eur J Nucl Med Mol Imaging 2010; 37: 920-933.
45. Westfall PJ, Young SS: Resampling-Based Multiple Testing. New York, Wiley, 1993.
46. Van Oudenhove L, Coen SJ, Aziz Q: Functional brain imaging of gastrointestinal sensation in health and disease. World J Gastroenterol 2007; 13: 3438-3445.
47. Kano M, Farmer AD, Aziz Q, Giampietro VP, Brammer MJ, Williams SC, Fukudo S, Coen SJ: Sex differences in brain response to anticipated and experienced visceral pain in healthy subjects. Am J Physiol Gastrointest Liver Physiol 2013; 304:G687-G699.
48. Ploghaus A, Narain C, Beckmann CF, Clare S, Bantick S, Wise R, Matthews PM, Rawlins JN, Tracey I: Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J Neurosci 2001; 21: 9896-9903.
49. Engeli S: Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. Handb Exp Pharmacol 2012; 209: 357-381.
50. Maldonado R, Valverde O, Berrendero F: Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 2006; 29: 225-232.
51. Petrovic P, Dietrich T, Fransson P, Andersson J, Carlsson K, Ingvar M: Placebo in emotional processing - induced expectations of anxiety relief activate a generalized modulatory network. Neuron 2005; 46: 957-969.
52. De la Fuente-Fernández R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ: Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001; 293: 1164-1166.
53. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK: Individual differences in reward responding explain placebo-induced expectations and effects. Neuron 2007; 55: 325-336.
54. Leknes S, Tracey I: A common neurobiology for pain and pleasure. Nat Rev Neurosci 2008; 9: 314-320.
55. Petrovic P, Pleger B, Seymour B, Klöppel S, De Martino B, Critchley H, Dolan RJ: Blocking central opiate function modulates hedonic impact and anterior cingulate response to rewards and losses. J Neurosci 2008; 28: 10509-10516.
56. Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, Meyer CR, Koeppe RA, Stohler CS: Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 2001; 293: 311-315.
57. Potvin S, Grignon S, Marchand S: Human evidence of a supra-spinal modulating role of dopamine on pain perception. Synapse 2009; 63: 390-402.
58. Volkow ND, Wang GJ, Baler RD: Reward, dopamine and the control of food intake: implications for obesity. Trends Cogn Sci 2011; 15: 37-46.
59. Di Marzo V: Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008; 7: 438-455.
60. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ, Gorzalka BB: Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005; 30: 508-515.
61. Goffin K, Van Paesschen W, Van Laere K: In vivo activation of endocannabinoid system in temporal lobe epilepsy with hippocampal sclerosis. Brain 2011; 134: 1033-1040.